<DOC>
	<DOCNO>NCT02159716</DOCNO>
	<brief_summary>Phase I study establish safety feasibility intravenously administer lentiviral transduce CART-meso cell administer without cyclophosphamide 3+3 dose escalation design patient metastatic pancreatic cancer , serous epithelial ovarian cancer , pleural mesothelioma . Dose : 1-3xE7 /mE2 ( Cohort 1 2 ) 1-3xE8 /mE2 ( Cohort 3 4 ) CAR+ T cell intravenous route . In event 2 DLTs dose level , dose deescalate 10-fold .</brief_summary>
	<brief_title>CART-meso Mesothelin Expressing Cancers</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically confirm cancer ( one follow ) : Metastatic pancreatic adenocarcinoma . Persistent recurrent serous epithelial ovarian cancer primary peritoneal carcinoma Malignant pleural mesothelioma ( histologically confirm epithelial ) Failure least one prior standard care chemotherapy advance stage disease . Subjects must measureable disease define RECIST 1.1 criterion modify RECIST criterion . Patients &gt; 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy &gt; 3 month . Satisfactory organ bone marrow function define follow ( note , minimal blood count absence transfusion cytokine support ) : . Absolute neutrophil count &gt; 1,000/μl ii . Platelets &gt; 75,000/μl iii . Hemoglobin &gt; 9 g/dL iv . Bilirubin &lt; 2.0x institutional normal upper limit unless secondary bile duct obstruction tumor v. Creatinine &lt; 1.5x institutional normal upper limit vi . Albumin ≥2 vii . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5x institutional normal upper limit viii . Cardiac ejection fraction &gt; 55 % measure rest echocardiogram , significant pericardial effusion . Blood coagulation parameter : PT international normalize ratio ( INR ) ≤ 1.5 PTT &lt; 1.2 time upper limit normal unless patient therapeutically anticoagulated history cancerrelated thrombosis stable coagulation parameter . Ability understand willingness provide write informed consent . Male Female subject reproductive potential agree use approve contraceptive method ( e.g . birth control pill , barrier device , intrauterine device , abstinence ) abstain method conception study 6 month follow study cell infusion proof sterility . Exclusion Criteria Sarcomatoid MPM histology know literature express mesothelin ; biphasic MPM also exclude . Participated trial receipt investigational study drug occur within 28 day prior enrollment anticipate treatment another investigational product study . This refer noncommercially approve investigational drug different use protocol . Anticipated need systemic chemotherapy within 2 week apheresis infusion CARTmeso cell . Active invasive cancer one three cancer study . Patients active noninvasive cancer ( nonmelanoma skin cancer , superficial cervical bladder prostate cancer PSA level &lt; 1.0 ) excluded.CARTmeso mesothelin express cancer HIV , HCV , HBV infection Active autoimmune disease ( include limit : systemic lupus erythromatosis , Sjogren 's syndrome , rheumatoid arthritis , psoriasis , multiple sclerosis , inflammatory bowel disease , etc . ) require immunosuppressive therapy within past 4 week , exception thyroid replacement . Patients ongoing active infection . Planned concurrent treatment systemic high dose corticosteroid . Patients may stable low dose steroid ( &lt; 10mg equivalent prednisone ) chronic respiratory condition . Patients require supplemental oxygen therapy . Prior therapy gene modify cell . Previous experimental therapy SS1 moiety , murine chimeric antibody ( human humanize antibody allow ) . History allergy murine proteins History allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) Any clinically significant pericardial effusion ; CHF ( NY Heart Association Grade IIIV ) cardiovascular condition would preclude assessment mesothelin induce pericarditis may worsen result toxicity expect study . This determination make cardiologist . Any clinically significant pleural peritoneal effusion drain standard approach . An indwelling drainage device place prior enrollment acceptable . Pregnant breastfeed woman . Female study participant reproductive potential must negative urine pregnancy test enrollment . A serum pregnancy test perform within 2 week infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Subjects</keyword>
</DOC>